We are live on ! Find out more
EBAC

European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC

Delisted

EBAC was delisted on the 2nd of March, 2023.

Back to rankings

41 hedge funds and large institutions have $55.2M invested in European Biotech Acquisition Corp. Class A Ordinary Shares in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

37% more capital invested

Capital invested by funds: $40.2M → $55.2M (+$15M)

32% more funds holding

Funds holding: 31 → 41 (+10)

Holders
41
Holders Change
+10
Holders Change %
+32.26%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
5
Reduced
1
Closed
–
Calls
$8K
Puts
–
Net Calls
+$8K
Net Calls Change
-$6K

Top Buyers

Rank Fund Capital Flow
1
Macquarie Group
Macquarie Group
Australia
+$4.87M
2
ACA
Arena Capital Advisors
California
+$2.18M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.89M
4
CCM
CAAS Capital Management
New York
+$935K
5
GF
Gabelli Funds
New York
+$709K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$183K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$6.05M +$4.54K +469 +0.1%
Macquarie Group
2
Macquarie Group
Australia
$4.87M +$4.87M +504,000 New
LA
3
Linden Advisors
New York
$4.84M – – –
Marshall Wace
4
Marshall Wace
United Kingdom
$3.15M – – –
ACA
5
Arena Capital Advisors
California
$2.93M +$2.18M +225,899 +301%
SCM
6
Suvretta Capital Management
New York
$2.9M – – –
WP
7
Woodline Partners
California
$2.67M – – –
MI
8
MMCAP International
Cayman Islands
$2.42M – – –
D.E. Shaw & Co
9
D.E. Shaw & Co
New York
$2.21M +$1.89M +195,697 +587%
RCM
10
Radcliffe Capital Management
Pennsylvania
$1.95M – – –
SC
11
Sculptor Capital
New York
$1.93M – – –
Alyeska Investment Group
12
Alyeska Investment Group
Illinois
$1.45M – – –
FTCM
13
Fir Tree Capital Management
New York
$1.45M – – –
AC
14
Athanor Capital
New York
$1.43M – – –
Millennium Management
15
Millennium Management
New York
$1.26M -$183K -18,900 -13%
PMAM
16
Picton Mahoney Asset Management
Ontario, Canada
$1.22M – – –
GCM
17
Ghisallo Capital Management
Massachusetts
$1.21M – – –
MCM
18
Moore Capital Management
New York
$1.21M – – –
DCM
19
Dupont Capital Management
Delaware
$971K – – –
AA
20
AQR Arbitrage
Connecticut
$969K +$544K +56,210 +128%
Hudson Bay Capital Management
21
Hudson Bay Capital Management
Connecticut
$967K – – –
TCM
22
Tenor Capital Management
New York
$967K – – –
CCM
23
CAAS Capital Management
New York
$935K +$935K +96,710 New
GF
24
Gabelli Funds
New York
$711K +$709K +73,303 New
GCIA
25
Gabelli & Co Investment Advisers
New York
$637K +$635K +65,689 New
1
2

EBAC Hedge Fund Activity: Q3 2021 in Review

41 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q3 2021, worth a combined $55.2M — up 37% from $40.2M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new EBAC positions and 0 closed out — a net gain of 10 holders — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Macquarie Group, opening a new position worth an estimated $4.87M. The largest seller was Millennium Management, cutting an estimated $183K.

  • 41 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q3 2021, up from 31 in Q2 2021.
  • Funds reported $55.2M of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q3 2021, up 37% quarter-over-quarter.
  • 10 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q3 2021 and 0 closed out, a net change of +10 holders.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares buyer in Q3 2021 was Macquarie Group, an estimated $4.87M added.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares seller in Q3 2021 was Millennium Management, an estimated $183K sold.

Based on aggregated 13F filings for Q3 2021.